CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stock (or prefunded warrants in lieu thereof) along with warrants to purchase up to 1,889,764 shares of common stock at a combined public offering price ofย $3.175ย per share and associated warrant. The company noted that common warrants will be immediately exercisable at $3.03ย per share and will expire five years following the initial exercise date. According to the announcement, the offering is expected to close on or aboutย Dec. 5, 2022, and will be subject to customary closing conditions. CNS Pharmaceuticals anticipates using the funds from the net proceeds for its ongoing clinical trial, other research and development, and working capital. H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering with Brookline Capital Markets, a division of Arcadia Securities LLC, acting coplacement agent for the offering.
To view the full press release, visitย https://ibn.fm/4Q7Ov
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals isย a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The companyโs lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information about the company, please visitย www.CNSPharma.com
NOTE TO INVESTORS:ย The latest news and updates relating to CNSP are available in the companyโs newsroom atย https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2)ย BioMedNewsBreaksย that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in todayโs market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text โBiotechโ to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visitย https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:ย http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of theย InvestorBrandNetwork
